Take a Look down Ignyta’s Developmental Pipeline

Learn more below about Ignyta’s portfolio of precision therapeutics in development. Our Rx pipeline works hand-in-hand with our molecular diagnostic technologies, resulting in faster confirmation of patient eligibility for an Ignyta clinical trial.

Entrectinib achieved an overall response rate of 79% in patients with NTRK, ROS1 or ALK fusion-positive extracranial disease [n = 24] and achieved both complete and durable responses in patients with CNS disease in Phase I studies.

RET gene fusions with potential to respond to RXDX-105 were reported in lung adenocarcinoma, thyroid cancer, and colorectal cancer, among other solid tumors.

The hedgehog pathway is a cancer stem cell pathway that has been implicated in drug resistance. Combinations of various therapies could be explored to help eradicate residual disease.

RXDX-106 is a potent, pseudo-reversible inhibitor designed to form non-covalent bonds with each target molecule to achieve a longer period of potential tumor-suppressing activity, which could be useful for potential single agent and combination therapies.